Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04001400
Other study ID # SNUBH-DHLIDRA
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 10, 2012
Est. completion date May 21, 2014

Study information

Verified date June 2019
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, randomized, open-label clinical study to assess the treatment response of high-dose rabeprazole compared with standard-dose rabeprazole in patients with extra-esophageal manifestations of gastroesophageal reflux disease.


Description:

Gastroesophageal reflux disease is a condition in which reflux of stomach contents into the esophagus. This disease can be classified in to two subtypes according to the symptoms; Typical symptoms such as heartburn and regurgitation, and atypical symptoms (extra-esophageal symptoms) such as chronic cough, asthma, non-cardiac chest pain, globus sensation, etc.

Acid suppression with proton pump inhibitors is the mainstream of therapy for the extra-esophageal manifestation as well as the typical symptoms of gastroesophageal reflux disease.

However, there is controversy about the efficacy of proton pump inhibitors on extra-esophageal reflux.

Therefore, we aimed to assess the effect of proton pump inhibotor (rabeprazole) on the extra-esophageal manifestation of gastroesophageal reflux disease, through comparison of treatment response with high-dose and standard-dose rabeprazole.


Recruitment information / eligibility

Status Completed
Enrollment 73
Est. completion date May 21, 2014
Est. primary completion date May 21, 2014
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- Age is over 20 years old, under 80 years old, men or women

- Patients who had experienced extra-esophageal symptoms of gastroesophageal reflux disease more than once a week within the last month prior to the start of the study

Exclusion Criteria:

- Patients administered with prokinetics, H2 receptor antagonists, proton pump inhibitors, anticholinergic drugs or non-steroid anti-inflammatory drugs prior to study in 4 weeks

- Patients administered with anti-thrombotic drugs

- Patients taking other investigational drugs or participating in other clinical studies in 4 weeks

- Patients with esophageal stricture, esophageal varix, Barrett's esophagus, peptic ulcer or gastrointestinal bleeding

- Patients with Zollinger-Ellison syndrome

- Patients with any kind of malignant tumor

- Patients with surgery related to gastroesophageal

- Patients with significant cardiovascular, pulmonary, heptic, renal, hemopoietic or endocrine system primary disease

- Patients with neuropsychiatric disorder, alcoholism, or drug abuse

- Women either pregnant or breast feeding

Study Design


Intervention

Drug:
Rabeprazole 20mg bid
Rabeprazole 20mg tablet b.i.d.
Rabeprazole 20mg qd
Rabeprazole 20mg tablet q.d.

Locations

Country Name City State
Korea, Republic of Seoul National University Bungdang Hospital Seongnam-si Gyeonggi-do

Sponsors (2)

Lead Sponsor Collaborator
Seoul National University Hospital IlDong Pharmaceutical Co Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effective improvement of symptoms A percentage of subjects showed effective improvement of extra-esophageal symptoms of gastroesophageal reflux disease by assessing the average sum of the questionnaire symptom scores.
The definition of "effective improvement" is the subjects showed =50% reduction from the initial questionnaire score.
The symptom questionnaire consists of a 5-graded Likert scale for each symptom to assess intensity of symptoms.
[score 0: no symptoms, score 1: mild symptoms that is not easily felt, score 2: moderate symptoms but not affect daily life, score 3: severe symptoms that hinder daily life or sleep, score 4: very severe symptoms that cannot lead to normal daily life or sleep]
In this trial, extra-esophageal symptoms consist of eight symptoms; non-cardiac chest pain, cough, globus, wheezing, laryngopharyngitis, hoarseness, belching and dysphagia.
8 weeks
See also
  Status Clinical Trial Phase
Completed NCT02105506 - Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses N/A
Completed NCT01360515 - A Study of Disposable Transnasal Esophagoscope N/A
Recruiting NCT02526095 - The French EsoGastricTumours Data Base
Completed NCT03998969 - Efficacy of DA-5204 on Gastroesophageal Reflux Disease Phase 3
Completed NCT01927016 - Outcomes After Esophageal Cancer Surgery N/A